More promising data came from the study of Rice et al., which showed that Fresolimumab, a high-affinity neutralizing antibody targeting all three TGF-β isoforms, significantly improved skin disease with a concomitant reduction in dermal myofibroblast infiltration, and lowered the expression of the gene thrombospondin-1 (THBS1), a biomarker of SSc skin disease highly upregulated by TGF-β (Figure 1). The gene discussed is THBS1; the disease is systemic sclerosis.